Previous uncontrolled reports have suggested that H 2 -antagonists may possess immunomodulatory activity in human immunodeficiency virus (HIV)-infected patients. Such trials reported improvements in HIV-related symptoms, increased absolute CD4 cell numbers, and improvements in other measures of host immunity. The present trial was a randomized, placebo-controlled, double-blind trial of ranitidine 300 mg (orally twice daily) in subjects with early HIV infection (absolute CD4 cells, 400-700/mm 3 ). Eighty-one subjects entered the trial and 73 completed 16 weeks on study medications. There were no significant differences in the time-weighted average change from baseline between the 2 treatment groups in absolute CD4 cell number, plasma HIV RNA level, or most other surrogate markers of HIV infection. Serum b 2 -microglobulin levels were significantly lower in placebo than ranitidine recipients. Ranitidine should not be recommended for the treatment of HIVinfected patients unless it is used for established indications.
The pathogenesis of progressive human immunodeficiency drugs have been unable to offer dramatic and enduring immunorestoration by themselves [6] . New strategies are needed to virus (HIV) infection is intimately related to a massive, wideaccomplish the complementary goals of potent viral suppresspread infection of lymphoid tissue that is chronically active sion and meaningful immunologic reconstitution. [1, 2] . Antiretroviral drugs can provide potent suppression of Cimetidine and ranitidine, both histamine H 2 -receptor antag-HIV activity [3] , modest increases in absolute CD4 lymphocyte onists, can increase the cell-mediated cytotoxicity and lymphocounts [3] , and a temporary delay in the clinical progression of cyte proliferative responses of human lymphocytes in vitro and HIV disease [4, 5] . However, currently available antiretroviral in vivo [7] . The spectrum of their activities includes inhibition of the regulatory functions of T suppressor cells [8] , enhancement of delayed-type hypersensitivity (DTH) responses [9, 10] CD4 cell counts or serum p24 antigen levels in the recipients of cimetidine [14] . Given the need for immunorestorative therapy in HIV-infected patients and the equivocal evidence of H 2 -Results receptor antagonist activity in these patients, we performed a double-blind, placebo-controlled study to evaluate ranitidine in Study subjects. Between June 1993 and March 1994, 81 patients were enrolled in the study. Their baseline demographic subjects with asymptomatic HIV infection.
and clinical characteristics are listed in table 1. The 2 patient populations were well balanced with regard to age, gender, race/ethnicity, risk behaviors, absolute CD4 lymphocyte Methods counts, and plasma HIV RNA levels.
Patient disposition. Eight patients withdrew before study
Study sample. This study enrolled subjects with documented HIV-1 infection and absolute CD4 lymphocyte counts of 400-completion; 5 had been assigned to ranitidine and 3 to placebo. The majority of these patients (5/8) failed to return for their days prior to study entry or during the trial. All subjects had CDC follow-up appointments.
class A infection with a Karnofsky performance status of 100%.
Immunologic observations. The comparisons of immuno- and there was no significant difference in the DAVGT of absoStudy design and treatment regimen. This study was a multicenter, randomized, double-blind, placebo-controlled trial of ranitidine in the treatment of asymptomatic subjects with HIV subjects with progressive HIV disease, perhaps a patient population too advanced to receive any benefit from H 2 -antagonists.
NOTE. Immunologic and virologic observations are presented as timeweighted average difference from baseline (DAVGT).
To elucidate the potential utility of ranitidine in subjects with * Comparisons were made using van Elteren test, controlling for investigator.
early HIV infection, our clinical trial was placebo-controlled, † Followed only in 15 subjects who had baseline values §15.6 pg/mL. focused principally on immunologic and viral surrogate markers of probable or definite prognostic significance, and included a more homogeneous patient population with 400-700 CD4 lute CD4 lymphocytes over 16 weeks. The DAVGT of CD4 cells/mm 3 at baseline. Our primary outcome measure was lymphocyte percentage, absolute CD8 lymphocyte counts and change from baseline in absolute CD4 cell count, and a percentages, absolute NK cell (CD56/CD16) counts and perpoststudy power analysis revealed that the sample size for this centages over 16 weeks also did not differ between the 2 trial offered 80% power to detect a difference of 53 cells/mm 3 groups. The 16-week DAVGT of b 2 -microglobulin levels was between groups at the .05 level of significance. Thus, it is significantly different between ranitidine and placebo recipients unlikely that a type II error has been made in reaching our (P Å .033); the ranitidine recipients had higher levels. The conclusion about ranitidine's lack of effect on absolute CD4 16-week DAVGT of neopterin levels revealed no significant lymphocyte numbers. difference between the 2 groups. DTH results at week 16 We believe that controlled trials are essential in the evaluashowed new responses in 5 of 43 placebo recipients and 0 tion of investigational immunomodulatory therapies for HIV of 38 ranitidine recipients (P Å .057, data not shown). The infection, a point that is underscored by this study. Although immunologic results did not differ in an on-treatment analysis.
early pilot trials may collect data on a spectrum of immunologic Virologic observations. The comparisons of virologic oband virologic variables, primary outcome measures in pivotal servations over 16 weeks are presented in table 2. Plasma HIV trials should assess prognostic markers of established signifi-RNA levels changed very little in both groups, and there was cance, such as absolute CD4 cell number or plasma HIV RNA no significant difference in the 16-week DAVGT of log 10 level. Our results do not support immunologic or antiretroviral plasma HIV RNA levels between placebo and ranitidine recipibenefits in subjects with early HIV infection receiving ranitients. For subjects with detectable ICD p24 antigen at baseline dine. (n Å 15), the 16-week DAVGT of ICD p24 antigen levels also did not reveal a significant difference. The virologic results did not differ in an on-treatment analysis.
Adverse events. There was no significant difference in the
